Part of THE JOHNS HOPKINS UNIVERSITY
Clinical Trials
371
19 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2014
Active, not recruiting
7
1.9%
Completed
306
82.5%
Enrolling By Invitation
3
0.8%
Not yet recruiting
9
2.4%
Recruiting
33
8.9%
Terminated
7
1.9%
Withdrawn
6
1.6%
No approval data available
- Pennsylvania health officials reported four breakthrough measles cases in fully vaccinated residents, the first such cases in the state's 2026 outbreak. - The state's outbreak has reached 676 cases with 124 hospitalizations, making it Pennsylvania's largest measles outbreak in more than 30 years. - MMR vaccination demand surged in August, with providers administering 46,000 doses versus the typical 25,000 per month. - Two measles-associated infant deaths have been reported, though state and federal officials disagree on whether both should be linked to the outbreak.
- A Johns Hopkins-led study analyzing over 2 million prescription attempts found insurance rejections for single-source brand-name drugs rose from 24.3% in 2018 to 40.7% in 2024, a 67% increase. - Nearly half (48.4%) of initially rejected prescriptions were not filled with the prescribed drug or a therapeutic alternative within 90 days, with patients who did obtain treatment waiting an average of 12 days. - GLP-1 receptor agonists for weight loss had the highest rejection rate at 85%, while oral anticoagulants had the lowest at 6.7%, highlighting wide variation across therapeutic classes. - Utilization management rules, including prior authorization and formulary exclusions, were the primary driver of rising denials, with commercial and Medicaid managed care plans experiencing the sharpest increases.
- West Virginia University and Johns Hopkins Bloomberg School of Public Health are continuing their Rural Health Initiative series with virtual discussions on social prescribing and maternal cardiovascular health. - The social prescribing session on July 20, 2026, will explore how referrals for services like transportation and food delivery can bridge gaps in rural healthcare access. - A second session on August 3, 2026, will focus on the Mountain Mama & Baby Cohort Study and cardiovascular health in pregnancy, addressing rural research infrastructure. - Both events support a recently announced research partnership between the two schools aimed at advancing joint solutions for shared rural health challenges.
- Powassan virus cases in the US surged to a record 76 diagnoses in 2025, up from just one case reported in 2004, according to CDC data. - Unlike Lyme disease requiring 36–48 hours of tick attachment, Powassan can transmit in as little as 15 minutes after an infected tick bite. - Approximately 10% of severe neurological Powassan cases are fatal, and many survivors experience lasting neurological damage. - No vaccine or specific treatment exists; clinical management is limited to supportive care including IV fluids and respiratory support.
- A retrospective study published August 26, 2026 in Health Affairs Scholar links DecisionRx's pharmacist-led medication therapy optimization program to 19.4% lower medical costs in a Medicare ACO population. - Savings deepened with program exposure, reaching 31.9% ($462 per member per month) after a nine-month implementation window, with results significant at p < 0.001. - Matched analysis of 1,003 treated patients and 14,031 controls showed 43.1% fewer inpatient admissions, 41.3% fewer emergency department visits, and 28.3% fewer outpatient visits. - Johns Hopkins Bloomberg School of Public Health faculty are separately collaborating with DecisionRx to generate real-world evidence on pharmacogenomics-guided medication management in value-based care.
- Maryland's Prescription Drug Affordability Board has recommended upper payment limits of $197 for Jardiance and $178.50 for Farxiga, marking the first concrete price controls under the state's expanded PDAB authority. - The Board has deemed four major diabetes drugs "unaffordable" including Boehringer Ingelheim's Jardiance, AstraZeneca's Farxiga, Novo Nordisk's Ozempic, and Eli Lilly's Trulicity following extensive public consultations and data reviews. - Maryland's PDAB model is being closely watched by other states as a potential solution to drug affordability challenges, with the Board's authority recently expanded to cover all state residents rather than just state employees. - The initiative faces ongoing concerns from patient advocacy groups about potential access restrictions, though Board members argue that lower prices should improve rather than limit pharmaceutical access.
- Brazil's national drug regulator approved the world's first single-dose dengue vaccine, Butantan-DV, for use in people aged 12 to 59, marking a significant breakthrough in dengue prevention. - The vaccine demonstrated 74.7% overall efficacy and 91.6% efficacy against severe forms of dengue in late-stage trials involving 16,000 volunteers across Brazil. - The single-dose format will particularly benefit remote communities in hard-to-reach regions like the Amazon, eliminating the need for multiple clinic visits required by existing two-dose vaccines. - Brazil plans to incorporate the vaccine into its national immunization program by early 2026, with over 1 million doses ready for distribution following the country's worst dengue epidemic with 6.4 million cases and 5,972 deaths in 2024.
- SCYNEXIS announced federal funding for a five-year, $7 million annual grant supporting development of next-generation triterpenoid antifungals (fungerps) to combat resistant fungal infections. - The collaboration between Hackensack Meridian CDI and Johns Hopkins researchers aims to advance fungerp candidates from preclinical stage to IND-ready status with enhanced pharmacological properties. - With approximately four million annual deaths globally attributed to fungal infections, the NIH-funded initiative addresses a critical unmet medical need in antimicrobial resistance. - The triterpenoid antifungal class represents the first new antifungal compounds approved since 2001, with ibrexafungerp already FDA-approved for vulvovaginal candidiasis treatment.
- States enforcing abortion bans after the Dobbs decision experienced a 6% overall increase in infant mortality rates, resulting in 478 additional infant deaths compared to pre-ban projections. - Non-Hispanic Black infants were disproportionately affected with an 11% increase in mortality rates, highlighting significant racial disparities in the impact of abortion restrictions. - Texas showed the most dramatic impact with a 9.4% rise in infant deaths, while researchers noted an increase in births with fatal congenital anomalies in states where abortion was previously an option for such cases.
- The FDA announced it will phase out requirements for animal testing of monoclonal antibodies and other drugs, citing the availability of "more effective, human-relevant methods" for safety evaluation. - The initiative aims to improve drug safety, accelerate evaluation processes, reduce R&D costs, and ultimately lower drug prices by implementing AI-based computational models, humanoid models, and real-world human data. - This regulatory shift, enabled by the bipartisan FDA Modernization Act 2.0 of 2022, represents what FDA Commissioner Marty Makary calls "a paradigm shift in drug evaluation" that could expedite development of new treatments.
